Illinois, Oprah pursue acai scammers
This article was originally published in The Tan Sheet
Executive Summary
The Illinois attorney general's office files consumer fraud lawsuits against three acai berry product suppliers and an affiliate marketer for "using misleading sales tactics to scam consumers." Additionally, Oprah Winfrey's Harpo Inc. and Dr. Mehmet Oz filed suit against 40 Internet supplement marketers for trademark infringement. Winfrey and Oz tout the health benefits of acai and red wine-based resveratrol but do not endorse specific products, as suggested by marketers. The Illinois AG's complaints, filed Aug. 19 in the Circuit Court of Cook County, name Netalab, Crush LLC, Amirouche & Norton LLC and others who use a "free trial" hook to lure consumers into continuity programs that are difficult to cancel. The Federal Trade Commission is cracking down on Web sites using "negative-option" marketing and making unrealistic weight-loss claims for acai supplements (1"The Tan Sheet" March 30, 2009)
You may also be interested in...
MonaVie settles with Oprah
The acai berry product firm resolves allegations it used Oprah Winfrey's and Dr. Mehmet Oz's names and images to promote acai products. An August 2009 suit named South Jordan, Utah-based MonaVie because of "unapproved distributor Web sites and social networking sites - all of which are now non-operational or shut down" (1"The Tan Sheet" Aug. 24, 2009, In Brief). The settlement requires the firm to not use Winfrey's or Oz's names, images or trademarks without permission. MonaVie distributors in violation will face "steep penalties," the company said. MonaVie avoids popular weight-loss claims for acai and focuses on science (2"The Tan Sheet" April 26, 2010)
Acai Offered As Bait In Latest Marketing Scams To Draw Investigations
Trendy supplement ingredient acai is the latest lure in what the Federal Trade Commission calls "negative-option" online marketing scams
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.